Our results elucidate a novel mechanism of fibroblast activation and IL-6 signaling by CAFs to establish an inflammatory niche and highlight circNOX4 as a promising candidate for CAF-targeted therapy in NSCLC. The gene discussed is IL6; the disease is non-small cell lung carcinoma.